Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avadel Pharmaceuticals (AVDL) Other Accumulated Expenses (2016 - 2022)

Historic Other Accumulated Expenses for Avadel Pharmaceuticals (AVDL) over the last 14 years, with Q3 2022 value amounting to $3.8 million.

  • Avadel Pharmaceuticals' Other Accumulated Expenses rose 15540.45% to $3.8 million in Q3 2022 from the same period last year, while for Sep 2022 it was $3.8 million, marking a year-over-year increase of 15540.45%. This contributed to the annual value of $5.3 million for FY2021, which is 134.62% up from last year.
  • Avadel Pharmaceuticals' Other Accumulated Expenses amounted to $3.8 million in Q3 2022, which was up 15540.45% from $2.1 million recorded in Q2 2022.
  • Avadel Pharmaceuticals' 5-year Other Accumulated Expenses high stood at $5.3 million for Q4 2021, and its period low was $1.4 million during Q1 2022.
  • Moreover, its 5-year median value for Other Accumulated Expenses was $3.1 million (2018), whereas its average is $2.9 million.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first skyrocketed by 50971.52% in 2018, then tumbled by 5712.62% in 2021.
  • Avadel Pharmaceuticals' Other Accumulated Expenses (Quarter) stood at $3.6 million in 2018, then grew by 6.46% to $3.9 million in 2019, then skyrocketed by 34.19% to $5.2 million in 2020, then rose by 1.35% to $5.3 million in 2021, then fell by 28.71% to $3.8 million in 2022.
  • Its Other Accumulated Expenses was $3.8 million in Q3 2022, compared to $2.1 million in Q2 2022 and $1.4 million in Q1 2022.